HAIFA, Israel, Jan. 7, 2013 (GLOBE NEWSWIRE) --
Dear Pluristem Shareholders,
In 2012 we have made great progress and moved closer to fulfilling our vision of being a leader in developing and manufacturing cell therapies. We have had significant achievements in many areas including:
